Traws Pharma Inc. (NASDAQ: TRAW) on Wednesday shared interim data from an ongoing randomized, open-label Phase 2 with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor.
Learn about comparable store sales, a measure of revenue growth relative to previous periods, and discover how it helps evaluate a retail location's performance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback